Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06311578 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
A Phase 1 study of Neoplasms, sponsored by Johnson & Johnson Enterprise Innovation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 10
- Study locations
NCT06311578: Recruiting Phase 1 study of Neoplasms, sponsored by Johnson & Johnson Enterprise Innovation.
NCT06311578 is a Phase 1 study of Neoplasms that is actively recruiting participants, run by Johnson & Johnson Enterprise Innovation. The registered enrollment target is 96 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (94% lower). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06311578, a Phase 1 study of Neoplasms, is actively recruiting participants, sponsored by Johnson & Johnson Enterprise Innovation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Primary Outcome
The DLTs are specific adverse events with defined non-hematological toxicities or hematologic toxicities as per the study protocol.
Conditions Studied
Interventions
- DRUG Cetrelimab
- DRUG JNJ-87704916
Study Locations (10)
Other
- Gustave Roussy - Villejuif
- Hosp Univ Vall D Hebron - Barcelona
- Hosp Univ Fund Jimenez Diaz - Madrid
- Hosp Univ Hm Sanchinarro - Madrid
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- UPMC Cancer Centers - Pittsburgh
New York
- NYU Langone Health - New York
Texas
- MD Anderson Cancer Center - Houston
Ontario
- Toronto General Hospital - Toronto
Quebec
- Centre Hospitalier de l'Universite de Montreal - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2024-04-10 |
| Est. Completion | 2032-08-26 |
| Phase | Phase 1 |
What NCT06311578 shows while recruiting
NCT06311578 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Cetrelimab is the first listed.
NCT06311578 lists 10 locations in 6 states (Other, Pennsylvania, New York).
Frequently Asked Questions
What is clinical trial NCT06311578 about?
NCT06311578 is a clinical study titled "A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors". The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
What is the current status of trial NCT06311578?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2024-04-10. Estimated completion is 2032-08-26.
What conditions does trial NCT06311578 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT06311578?
The interventions under investigation include: Cetrelimab (DRUG), JNJ-87704916 (DRUG).
Who is sponsoring clinical trial NCT06311578?
This trial is sponsored by Johnson & Johnson Enterprise Innovation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06311578 being conducted?
This trial has 10 study locations across New York, Pennsylvania, Texas, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06311578's enrollment target sits among peer trials
96 74th of 158 higher than 84 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI